Invention Grant
- Patent Title: Diagnostic anti-PD-L1 antibody and use thereof
-
Application No.: US16334699Application Date: 2017-09-20
-
Publication No.: US10738120B2Publication Date: 2020-08-11
- Inventor: Claudia Wilm , Klaus Schneider , Heike Dahmen
- Applicant: Merck Patent GmbH , Pfizer Inc.
- Applicant Address: DE Darmstadt US NY New York
- Assignee: Merck Patent GmbH,Pfizer Inc.
- Current Assignee: Merck Patent GmbH,Pfizer Inc.
- Current Assignee Address: DE Darmstadt US NY New York
- Agency: Haley Guiliano LLP
- Agent James F. Haley, Jr.; Brian M. Gummow
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@4858baaa
- International Application: PCT/EP2017/073712 WO 20170920
- International Announcement: WO2018/054940 WO 20180329
- Main IPC: C07K16/28
- IPC: C07K16/28 ; G01N33/574 ; C07K16/30 ; A61K45/06 ; A61P35/00 ; A61K39/395
Abstract:
The present invention provides for an antibody or antigen-binding fragment thereof which binds to an epitope within human PD-L1 with high specificity and reproducibility. The inventive antibody or antigen-binding fragment thereof may be used in assessing PD-L1 expression in tissue samples to aid in patient stratification. The present invention further provides methods of producing the inventive antibody.
Public/Granted literature
- US20190211104A1 Diagnostic Anti-PD-L1 Antibody and Use Thereof Public/Granted day:2019-07-11
Information query
